Reneo Pharmaceuticals (RPHM) Stock Chart & Stock Price History $1.48 +0.01 (+0.68%) (As of 07/19/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Reneo Pharmaceuticals Stock Price Performance5 Day Performance0.00%1 Month Performance-6.33%3 Month Performance-14.94%6 Month Performance-8.07%Year-To-Date Performance-7.50%1 Year Performance-76.36% Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Weiss RatingsWho’s partnering with Nvidia next?Nvidia's been quietly pivoting to another, potentially lucrative business. Nvidia's own CEO, Jensen Huang, believes Big Tech is going to spend over $1 trillion on this part of the business over the next four years.Find out more details on these three critical Nvidia partners immediately. RPHM Stock Chart for Friday, July, 19, 2024 RPHM Chart by TradingView Reneo Pharmaceuticals Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/18/2024$1.49$1.47-1.34%$1.53$1.4724,826 shs$49.13 million07/17/2024$1.52$1.49-1.97%$1.53$1.4837,641 shs$49.80 million07/16/2024$1.52$1.52$1.54$1.5016,244 shs$50.80 million07/15/2024$1.48$1.52+2.70%$1.54$1.4877,998 shs$50.80 million07/12/2024$1.51$1.48-1.99%$1.56$1.4895,750 shs$49.46 million07/11/2024$1.46$1.51+3.42%$1.57$1.49175,225 shs$50.46 million Get the Latest News and Ratings for RPHM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/10/2024$1.50$1.46-2.67%$1.52$1.4671,018 shs$48.79 million07/09/2024$1.47$1.50+2.04%$1.53$1.46109,231 shs$50.13 million07/08/2024$1.50$1.47-2.00%$1.52$1.46123,600 shs$49.13 million07/05/2024$1.51$1.50-0.66%$1.54$1.48262,196 shs$50.13 million07/04/2024$1.51$1.51$1.54$1.4872,409 shs$50.46 million07/03/2024$1.51$1.51$1.54$1.4872,409 shs$50.47 million07/02/2024$1.55$1.51-2.58%$1.57$1.51127,093 shs$50.46 million07/01/2024$1.51$1.55+2.65%$1.61$1.53127,518 shs$51.80 million06/28/2024$1.61$1.51-6.21%$1.63$1.511.65 million shs$50.46 million06/27/2024$1.57$1.61+2.55%$1.65$1.57115,249 shs$53.81 million06/26/2024$1.61$1.57-2.48%$1.62$1.57103,356 shs$52.47 million06/25/2024$1.62$1.61-0.62%$1.62$1.5965,069 shs$53.81 million06/24/2024$1.62$1.62$1.64$1.58129,659 shs$54.14 million06/21/2024$1.58$1.62+2.53%$1.64$1.56154,373 shs$54.14 million06/20/2024$1.58$1.58$1.60$1.57227,228 shs$52.80 million06/19/2024$1.58$1.58$1.67$1.57196,558 shs$52.81 million06/18/2024$1.65$1.58-4.24%$1.67$1.57195,613 shs$52.80 million06/17/2024$1.66$1.65-0.60%$1.68$1.62151,551 shs$55.14 million06/14/2024$1.70$1.66-2.35%$1.70$1.62148,635 shs$55.48 million06/13/2024$1.74$1.70-2.30%$1.73$1.67116,247 shs$56.81 million06/12/2024$1.71$1.74+1.75%$1.93$1.66443,086 shs$58.15 million06/11/2024$1.68$1.71+1.79%$1.73$1.6495,724 shs$57.15 million06/10/2024$1.67$1.68+0.60%$1.69$1.6461,328 shs$56.15 million06/07/2024$1.70$1.67-1.76%$1.69$1.6538,852 shs$55.81 million06/06/2024$1.70$1.70$1.72$1.6666,309 shs$56.81 million06/05/2024$1.66$1.70+2.41%$1.72$1.6568,217 shs$56.82 million06/04/2024$1.67$1.66-0.60%$1.68$1.6547,612 shs$55.48 million06/03/2024$1.66$1.67+0.60%$1.68$1.6638,485 shs$55.81 million05/31/2024$1.72$1.66-3.49%$1.72$1.61108,667 shs$57.48 million05/30/2024$1.69$1.72+1.78%$1.74$1.6750,682 shs$57.48 million05/29/2024$1.74$1.69-2.87%$1.79$1.6983,705 shs$56.48 million05/28/2024$1.66$1.74+4.82%$1.80$1.63146,593 shs$58.15 million05/27/2024$1.66$1.66$1.75$1.65135,100 shs$55.48 million05/24/2024$1.73$1.66-4.05%$1.75$1.65135,156 shs$55.48 millionAI’s Biggest Problem (Ad)Nvidia's been quietly pivoting to another, potentially lucrative business. Nvidia's own CEO, Jensen Huang, believes Big Tech is going to spend over $1 trillion on this part of the business over the next four years.Find out more details on these three critical Nvidia partners immediately.05/23/2024$1.83$1.73-5.46%$1.85$1.70138,154 shs$57.82 million05/22/2024$1.89$1.83-3.17%$1.90$1.79121,125 shs$61.16 million05/21/2024$1.90$1.89-0.53%$1.93$1.8199,507 shs$63.17 million05/20/2024$1.75$1.90+8.57%$1.92$1.65283,836 shs$63.50 million05/17/2024$1.66$1.75+5.42%$1.76$1.61204,722 shs$58.49 million05/16/2024$1.60$1.66+3.75%$1.68$1.58243,460 shs$55.48 million05/15/2024$1.62$1.60-1.23%$1.65$1.57421,355 shs$53.47 million05/14/2024$1.59$1.62+1.89%$1.66$1.421.46 million shs$54.14 million05/13/2024$1.81$1.59-12.15%$1.73$1.556.38 million shs$53.14 million05/10/2024$1.86$1.81-2.69%$1.87$1.8067,284 shs$60.49 million05/09/2024$1.83$1.86+1.64%$1.89$1.8383,118 shs$62.16 million05/08/2024$1.74$1.83+5.17%$1.89$1.72284,836 shs$61.16 million05/07/2024$1.73$1.74+0.58%$1.78$1.71117,635 shs$58.15 million05/06/2024$1.74$1.73-0.57%$1.77$1.7147,121 shs$57.82 million05/03/2024$1.73$1.74+0.58%$1.77$1.72110,683 shs$58.15 million05/02/2024$1.71$1.73+1.17%$1.75$1.7040,579 shs$57.82 million05/01/2024$1.67$1.71+2.40%$1.77$1.67107,875 shs$57.15 million04/30/2024$1.67$1.67$1.70$1.6693,297 shs$55.81 million04/29/2024$1.67$1.67$1.67$1.64171,814 shs$55.81 million04/26/2024$1.65$1.67+1.21%$1.71$1.66115,223 shs$55.81 million04/25/2024$1.68$1.65-1.79%$1.68$1.62119,607 shs$55.14 million04/24/2024$1.68$1.68+0.30%$1.70$1.66138,349 shs$56.15 million04/23/2024$1.69$1.68-0.89%$1.72$1.6478,044 shs$55.98 million04/22/2024$1.74$1.69-2.87%$1.74$1.65181,894 shs$56.48 million04/19/2024$1.76$1.74-1.14%$1.75$1.7082,987 shs$58.15 million04/18/2024$1.77$1.76-0.56%$1.78$1.7076,424 shs$58.82 million Related Companies: MIST Stock Chart TRVI Stock Chart BMEA Stock Chart XBIT Stock Chart RZLT Stock Chart RANI Stock Chart PYXS Stock Chart GBIO Stock Chart SKYE Stock Chart VTYX Stock Chart Receive RPHM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:RPHM) was last updated on 7/19/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | Sponsoredhe’s your competitor in tradingWant a preview of how elite traders think?! For a limited time, you can claim AI SMS alerts from TradeAlgo ...TradeAlgo | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reneo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.